QPPV.COM KNOWLEDGE ASSESSMENT

GVP Module XVI Inspection Findings: Risk-Minimisation Measures in Practice

Test your understanding of the concepts covered by GVP Module XVI Inspection Findings: Risk-Minimisation Measures in Practice.

Question 1 of 10Pass mark: 80%

Question 1 of 10 Which approach best supports a defensible decision to maintain, modify or withdraw an RMM?

Use distribution totals alone because they are available across all markets Base the decision on whether the current materials have been approved Connect objective-matched evaluation results and their limitations to a documented decision and subsequent controlled practice Wait for an inspection finding before reconsidering the measure

Question 2 of 10 After an RMM is introduced, reported adverse events become less frequent. Which interpretation is most defensible without further evidence?

The RMM caused the reduction because the change followed its introduction The RMM is effective if the reduction is statistically significant in any dataset The reduction is evidence of effectiveness regardless of exposure or reporting changes The change may be consistent with effectiveness, but alternative explanations and data limitations must be assessed

Question 3 of 10 An EU-level RMM is well documented, but a national inspection finds that clinicians cannot complete the required action through the local healthcare pathway. What does this most strongly illustrate?

National implementation is outside pharmacovigilance inspection scope An EU-level document always demonstrates that the measure is operational locally Local adaptation is acceptable only if it removes the key safety objective A measure's effectiveness depends in part on whether its implementation works in the relevant national setting

Question 4 of 10 A current RMP describes a dispensing control that differs from the workflow used in one Member State. What is the most appropriate initial response?

Assume the RMP is correct and exclude local records from the inspection response Establish the discrepancy's history and impact, then control its resolution and assess any required regulatory action Treat any difference as conclusive proof that the RMM is ineffective Update the local procedure without assessing whether the change requires regulatory agreement or notification

Question 5 of 10 A deviation recurs across several countries, and the CAPA consists only of retraining the local staff involved. What is the main weakness in this response?

Training is never an appropriate CAPA Cross-country deviations must always be reported as a product quality defect A CAPA should not examine individual actions when a procedure exists The response may not address systemic causes such as unclear ownership, inaccessible systems or weak controls

Question 6 of 10 A revised educational material has been centrally approved. Which evidence would most directly address whether change control was effective?

Confirmation that the central file has a new version number A record that the medical department approved the change Evidence that the correct version reached intended users in time and that obsolete versions were removed or superseded A statement that all affiliates were informed that a revision was planned

Question 7 of 10 Which CAPA effectiveness check provides the strongest evidence that a revised dispensing control works?

Confirming that the revised procedure was approved and uploaded Tracing subsequent transactions to verify the required result was reviewed before supply Recording that affected staff attended a refresher session Asking managers whether they consider the new workflow easier to use

Question 8 of 10 An MAH outsources collection of implementation data for an RMM. Which statement best describes the MAH's responsibility?

The MAH remains responsible for its pharmacovigilance system and should oversee the subcontracted activity and its evidence Responsibility transfers to the vendor once the service agreement is signed The MAH is responsible only for the final report, not the quality of source data The vendor's quality system replaces the MAH's need for escalation and inspection support arrangements

Question 9 of 10 A national competent authority scopes an inspection to a specific RMM in its healthcare system. Which statement is most accurate?

National implementation can be an inspection focus, including how an agreed EU-level measure operates in that setting Only the European Medicines Agency can inspect implementation of centrally authorised products The authority may examine only the local translation, not the operational pathway National implementation is outside inspection scope if the RMP is centrally approved

Question 10 of 10 Which statement best describes the QPPV's role in oversight of RMMs?

The QPPV must personally approve every local material and perform every implementation activity The QPPV's role ends when the RMP is submitted The QPPV oversees the pharmacovigilance system and should receive timely information on material safety or RMM issues, without personally executing every activity The QPPV is responsible only for communicating confirmed adverse reactions to regulators

QPPV.com

GVP Module XVI Inspection Findings: Risk-Minimisation Measures in Practice

Cookie Settings